Price$3.71-0.02 (-0.54%)
01:30 PM06:00 PM
News · 26 weeks38-62%
2025-12-142026-06-07
Mix2090d
- Other7(35%)
- Insider5(25%)
- SEC Filings5(25%)
- Earnings3(15%)
Latest news
25 items- PRA Fresh FDA Catalyst Is Putting Regenerative Wound Care in FocusNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien
- PRThe Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement PartsIssued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome
- PRMIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor ConferenceMARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare.
- PRMIMEDX Announces Launch of G4Derm® PlusFlowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide. MIMEDX recently acquired exclusive distribution rights for G4Derm Plus in the United States, adding the innovative peptide matrix to its broadening portfolio of solutions for Surgical markets. "This launch showcases our efforts to leverage our sizable commercial reach to expand solutions available to clinici
- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
- SECSEC Form DEFA14A filed by MiMedx Group IncDEFA14A - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECMiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form DEF 14A filed by MiMedx Group IncDEF 14A - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 10-Q filed by MiMedx Group Inc10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRMIMEDX Announces First Quarter 2026 Operating & Financial ResultsReports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "The first quarter of 2026 was adversely impacted as new Medicare reimbursement policies in the advanced wound care space went into effect at the start of the year and led to significant confusion across the industry in nearly every care setting. Additio
- PRMIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13759618 A replay of the webcast will be available for approximately 30 days on the Company's
- SECMiMedx Group Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRMIMEDX Announces Restructuring and Cost Reduction InitiativeMARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio
- PRMIMEDX to Sponsor Leading Advanced Wound Care ConferencesMultispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care ("SAWC") Spring 2026 and MedStar Georgetown University Hospital's Diabetic Limb Salvage ("DLS") Conference. Through scientific presentations, clinician education, and exhibit presence, MIMEDX will highlight its growing body of clinical evidence and expanding portfolio of solutions designed to support clinicians in m
- PRMIMEDX Announces Launch of CHORIOFIX™MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts. "CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer," stated Michelle Massee, MIMEDX VP, Research & Development. "It consists of two chorion layers with an intact intermediate layer, making it our thickest product to date. The allograft's structure enhances handling, particularly during positioning and suturing, while its uniform, dual-side
- INSIDERGeneral Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 20,245 shares, decreasing direct ownership by 4% to 543,195 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 6,762 shares, decreasing direct ownership by 2% to 329,450 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly exercised 42,845 shares at a strike of $4.50 and covered exercise/tax liability with 21,270 shares, increasing direct ownership by 7% to 336,212 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERGeneral Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 61,460 shares and exercised 136,364 shares at a strike of $4.50, increasing direct ownership by 15% to 563,440 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Financial Officer Doug Rice exercised 243,000 shares at a strike of $4.50 and covered exercise/tax liability with 96,363 shares, increasing direct ownership by 55% to 412,315 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Executive Officer Capper Joseph H was granted 371,094 shares, increasing direct ownership by 70% to 904,656 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Financial Officer Doug Rice was granted 74,163 shares, increasing direct ownership by 39% to 265,678 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERGeneral Counsel and CAO Hulse William Frank Iv was granted 74,987 shares, increasing direct ownership by 18% to 488,536 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Operating Officer Whitlow Ricci S was granted 74,163 shares, increasing direct ownership by 19% to 462,825 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly was granted 74,163 shares, increasing direct ownership by 31% to 314,637 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
MDXG FAQ
6 questionsWhat does MiMedx Group Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective...Where does MDXG stock trade?
MiMedx Group Inc (MDXG) is listed on NASDAQ.What sector and industry is MDXG in?
MiMedx Group Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MDXG?
MiMedx Group Inc has had 7 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $1000.00 price target on 2026-02-23. Recent price targets range from $700.00 to $2300.00.What companies are similar to MDXG?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MDXG side-by-side with any of them on Quantisnow.How can I track MDXG on Quantisnow?
Quantisnow aggregates MiMedx Group Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDXG to receive live email and push alerts on every new disclosure.